gdc
FDA Approvals, News & UpdatesFollicular LymphomaNewsworthy

Aliqopa the Newest Treatment Approved for Relapsed Follicular Lymphoma

December 2017 Vol 3 No 6

On September 14, 2017, the FDA approved Aliqopa (copanlisib; from Bayer HealthCare) for the treatment of adults with relapsed follicular lymphoma who have received ≥2 previous systemic therapies.

“For patients with relapsed follicular lymphoma, the cancer often comes back even after multiple treatments. Options are limited for these patients and today’s approval provides an additional choice for treatment, filling an unmet need for them,” said Richard Pazdur, MD, Director of the FDA’s Oncology Center of Excellence.

The approval of Aliqopa was based on a clinical trial showing improved response to therapy with this drug. Serious side effects with Aliqopa include infections, high blood sugar and blood pressure, inflammation of lung tissue, neutropenia, and severe skin reactions. Women who are breastfeeding should avoid this drug.

Share this:

Recommended For You
Breast CancerFDA Approvals, News & Updates
FDA Approved Margenza for Patients with Metastatic HER2-Positive Breast Cancer
In December 2020, the FDA approved Margenza (margetuximab-cmkb), a new targeted therapy, for the treatment of patients with metastatic HER2-positive breast cancer, representing an important new option for patients with this type of breast cancer that continues to progress despite different treatments.
FDA Approvals, News & UpdatesLung Cancer
FDA Approves Tepmetko, New Targeted Therapy, for Patients with Metastatic Lung Cancer and MET Exon 14 Alterations
In February 2021, the FDA approved Tepmetko (tepotinib), a new oral targeted therapy, for the treatment of all adults with metastatic non–small-cell lung cancer and MET exon 14 alterations. Tepmetko is the first MET inhibitor that has been approved by the FDA.
FDA Approvals, News & UpdatesLung Cancer
Tagrisso Approved as Adjuvant Therapy for Patients with Lung Cancer and EGFR Mutations
In December 2020, the FDA approved Tagrisso (osimertinib) for adjuvant therapy (continued therapy to prevent cancer recurrence) after surgical removal of the tumor, in patients with non–small-cell lung cancer and EGFR exon 19 deletions or exon 21 L858R mutations. Tagrisso was previously approved for the treatment of other types of lung cancer.
FDA Approvals, News & UpdatesProstate Cancer
Orgovyx First FDA-Approved Oral Hormone Therapy for Patients with Advanced Prostate Cancer
In December 2020, the FDA approved Orgovyx (relugolix), as the first oral hormone therapy for the treatment of men with advanced prostate cancer. This new drug may eliminate the need to visit the clinic for treatment, helping patients with cancer avoid unnecessary exposure during the pandemic.
Last modified: January 2, 2018

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country